Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Athenex, Inc. (NASDAQ: ATNX).

Full DD Report for ATNX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATNX)

FDA revising collaboration with states to ensure access and quality of compounded drugs
In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines the steps the agency is taking to ensure the quality of compounded drugs while enabling access to patients in need. Key points: More news on: Diplomat Pharmacy, AmerisourceBergen Corporation, McKesson Corporation, Healthcare...
Source: SeekingAlpha
Date: September, 07 2018 11:24
Athenex announces positive recommendation by the DSMB and continues the Oraxol Phase III program
Athenex (NASDAQ: ATNX ) announces that the planned second interim analysis of the Oraxol 001 Phase III Clinical Trial in metastatic breast cancer has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB). More news on: Athenex, Inc., Healthcare stocks news, ...
Source: SeekingAlpha
Date: September, 05 2018 09:28
Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program
BUFFALO, N.Y., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the planned second inte...
Source: GlobeNewswire
Date: September, 05 2018 07:00
Endo up 5% on FDA plan to restrict compounding of vasopressin
Endo International ( ENDP +5.1% ) is up on average volume on the heels of the FDA's  proposed restriction on bulk compounding of three approved drugs, including vasopressin. More news on: Endo International plc, Athenex, Inc., Healthcare stocks news, Stocks on the move, Read mo...
Source: SeekingAlpha
Date: August, 27 2018 13:26
Athenex appoints Randoll Sze as Chief Financial Officer
Athenex (NASDAQ: ATNX ) appoints  Randoll Sze as Chief Financial Officer of the company. Mr. Sze will report to Athenex’s CEO, Dr. Johnson Lau. More news on: Athenex, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 20 2018 08:08
Athenex Appoints Randoll Sze as Chief Financial Officer
BUFFALO, N.Y., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Randoll S...
Source: GlobeNewswire
Date: August, 20 2018 08:00
Athenex's (ATNX) CEO Johnson Lau on Q2 2018 Results - Earnings Call Transcript
Athenex Inc. (ATNX) Q2 2018 Earnings Conference Call August 14, 2018 9:00 AM ET Executives Tim McCarthy – Managing Director of LifeSci Advisors Johnson Lau – Chief Executive officer Jeff Yordon – Chief Operating Officer Rudolf Kwan – Chief Medical O...
Source: SeekingAlpha
Date: August, 14 2018 19:39
Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update
Second quarter revenue increased to $11.6 million compared to $4.6 million in the same period last year. Received a strategic investment of $100 million from Perceptive Advisors Primary endpoints achieved in two Phase 3 trials of KX2-391 in Actinic Keratosis In-licensed an immu...
Source: GlobeNewswire
Date: August, 14 2018 07:00
Portfolio moves by Greenwoods Asset Management
Greenwoods Asset Management discloses new portfolio moves in a fresh SEC filing. More news on: TAL Education Group, Huazhu Group Limited ADR, Qudian, Inc., Consumer stocks news, Tech stocks news, Read more ...
Source: SeekingAlpha
Date: August, 13 2018 09:00
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of compounded Vasopressin Injection...
Source: GlobeNewswire
Date: August, 13 2018 07:29

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0815.7915.8416.1415.52365,354
2018-05-1716.8817.0017.0416.71149,626

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1238,026232,28916.3701Cover
2018-12-1143,33153,76480.5948Short
2018-12-1011,74836,93831.8046Cover
2018-12-0717,89255,71832.1117Cover
2018-12-0624,45373,96933.0584Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATNX.


About Athenex, Inc. (NASDAQ: ATNX)

Logo for Athenex, Inc. (NASDAQ: ATNX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ATNX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 14 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 27 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: April, 27 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 27 2018

       

       


      Daily Technical Chart for (NASDAQ: ATNX)

      Daily Technical Chart for (NASDAQ: ATNX)


      Stay tuned for daily updates and more on (NASDAQ: ATNX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ATNX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATNX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATNX and does not buy, sell, or trade any shares of ATNX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/